Preclinical study demonstrates dynamic S-acylation controls IDH2 mitochondrial import to sustain redox balance, highlighting a metabolic vulnerability for cancer therapy.
Mitochondrial redox homeostasis is fundamental for cellular function, and its dysregulation is associated with various diseases, including cancer. Isocitrate dehydrogenase 2 (IDH2) is a key enzyme that maintains this balance by generating NADPH. However, the mechanisms controlling IDH2 subcellular localization remain incompletely understood. Here, we identify reversible S-acylation as a critical regulator of IDH2 localization. Using chemical reporters, we demonstrate that IDH2 is S-acylated at a conserved cysteine residue, mediated by ZDHHC3 and APT1. Loss of IDH2 S-acylation disrupts its mitochondrial localization by reducing its interaction with the mitochondrial import receptor TOMM20, leading to NADPH deficiency, redox imbalance, and impaired oxidative phosphorylation. Consistently, ZDHHC3 knockout phenocopies IDH2 S-acylation deficiency, impairing its mitochondrial localization and function. Genetic ablation of IDH2 S-acylation suppresses tumor growth in vitro and in vivo . Our work establishes dynamic S-acylation of IDH2 as an essential regulator of mitochondrial redox homeostasis, thereby revealing a potential metabolic vulnerability in cancer.
No takes yet. Share an insight, caveat, or question.
Miao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: